Infusion Pumps
Infusion Pumps, Implantable
Infusions, Intravenous
Infusions, Parenteral
Infusions, Intra-Arterial
Insulin Infusion Systems
Drug Therapy, Computer-Assisted
Anesthesia, Intravenous
Propofol
Hyperbaric Oxygenation
Anesthetics, Intravenous
Medication Errors
Equipment Failure
Floxuridine
Nerve Block
Anesthetics, Local
Amides
Drug Administration Schedule
Morphine
Dose-Response Relationship, Drug
Proton Pump Inhibitors
Ion Pumps
Distinct clinical and laboratory activity of two recombinant interleukin-2 preparations. (1/472)
Interleukin-2 (IL-2) is a potent lymphokine that activates natural killer cells, T cells, and other cells of the immune system. Several distinct recombinant human IL-2 preparations have shown antitumor activity, particularly for renal cell cancer and melanoma. Somewhat distinct immune and clinical effects have been noted when different IL-2 preparations have been tested clinically; however, the regimens and doses used were not identical. To compare these more directly, we have evaluated two clinical recombinant IL-2 preparations in vitro and in vivo using similar regimens and similar IUs of IL-2. We used the Food and Drug Administration-approved, commercially available Chiron IL-2 and the Hoffmann LaRoche (HLR) IL-2 supplied by the National Cancer Institute. Using equivalent IUs of IL-2, we noted quantitative differences in vitro and in vivo in the IL-2 activity of these two preparations. In patients receiving comparable IUs of the two preparations, HLR IL-2 induced the release of more soluble IL-2 receptor alpha into the serum than Chiron IL-2. In addition, more toxicities were noted in patients receiving 1.5 x 10(6) IU of HLR IL-2 than were seen in patients treated with 1.5 x 10(6) or even 4.5 x 10(6) IU of Chiron IL-2. These toxicities included fever, nausea and vomiting, and hepatic toxicity. In vitro proliferative assays using IL-2-dependent human and murine cell lines indicated that the IU of HLR IL-2 was more effective than Chiron IL-2 at inducing tritiated thymidine incorporation. Using flow cytometry, we also found quantitative differences in the ability of these two preparations to bind to IL-2 receptors. These findings indicate that approximately 3-6 IU of Chiron IL-2 are required to induce the same biological effect as 1 IU of HLR IL-2. (+info)Efficacy of ampicillin plus ceftriaxone in treatment of experimental endocarditis due to Enterococcus faecalis strains highly resistant to aminoglycosides. (2/472)
The purpose of this work was to evaluate the in vitro possibilities of ampicillin-ceftriaxone combinations for 10 Enterococcus faecalis strains with high-level resistance to aminoglycosides (HLRAg) and to assess the efficacy of ampicillin plus ceftriaxone, both administered with humanlike pharmacokinetics, for the treatment of experimental endocarditis due to HLRAg E. faecalis. A reduction of 1 to 4 dilutions in MICs of ampicillin was obtained when ampicillin was combined with a fixed subinhibitory ceftriaxone concentration of 4 micrograms/ml. This potentiating effect was also observed by the double disk method with all 10 strains. Time-kill studies performed with 1 and 2 micrograms of ampicillin alone per ml or in combination with 5, 10, 20, 40, and 60 micrograms of ceftriaxone per ml showed a > or = 2 log10 reduction in CFU per milliliter with respect to ampicillin alone and to the initial inoculum for all 10 E. faecalis strains studied. This effect was obtained for seven strains with the combination of 2 micrograms of ampicillin per ml plus 10 micrograms of ceftriaxone per ml and for six strains with 5 micrograms of ceftriaxone per ml. Animals with catheter-induced endocarditis were infected intravenously with 10(8) CFU of E. faecalis V48 or 10(5) CFU of E. faecalis V45 and were treated for 3 days with humanlike pharmacokinetics of 2 g of ampicillin every 4 h, alone or combined with 2 g of ceftriaxone every 12 h. The levels in serum and the pharmacokinetic parameters of the humanlike pharmacokinetics of ampicillin or ceftriaxone in rabbits were similar to those found in humans treated with 2 g of ampicillin or ceftriaxone intravenously. Results of the therapy for experimental endocarditis caused by E. faecalis V48 or V45 showed that the residual bacterial titers in aortic valve vegetations were significantly lower in the animals treated with the combinations of ampicillin plus ceftriaxone than in those treated with ampicillin alone (P < 0.001). The combination of ampicillin and ceftriaxone showed in vitro and in vivo synergism against HLRAg E. faecalis. (+info)Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. (3/472)
PURPOSE: To determine the maximum-tolerated dose (MTD), dose-limiting toxicities, and efficacy of gemcitabine combined with fluorouracil (5-FU) in patients with pancreatic cancer. PATIENTS AND METHODS: Patients with measurable, locally advanced, nonresectable or metastatic pancreatic cancer were candidates for the study. 5-FU was given via protracted venous infusion (PVI) at a fixed dosage of 200 mg/m2/d, and gemcitabine was administered weekly for 3 consecutive weeks every 4 weeks. The initial dose of gemcitabine was 700 mg/m2 and was escalated in increments of 100 mg/m2/wk until the appearance of severe toxicity. Measurements of efficacy included the following: response rate; clinical benefit response, which is a composite measurement of pain, performance status, and weight loss; time to disease progression; and survival. RESULTS: Twenty-six patients received a total of 109 courses. Dose-limiting toxicity, which consisted of grade 4 neutropenia with fever (one patient) and grade 4 thrombocytopenia (one patient), was observed in two of three patients treated with 1,100 mg/m2/wk of gemcitabine. On the basis of these results, the MTD of gemcitabine with 5-FU via PVI on this schedule was 1,000 mg/m2. Sixteen patients developed grade 3-4 neutropenia, and three patients developed grade 3-4 thrombocytopenia. Grade 3-4 nonhematologic toxicity consisted of diarrhea (two patients) and cutaneous toxicity, asthenia, edema, mucositis, and nausea and vomiting (one patient each). The delivered dose-intensity of gemcitabine was similar at the 1,000 mg/m2 dose level (599 mg/m2/wk) as at the 900 mg/m2 (601 mg/m2/wk) dose level. For this reason, the recommended dose of gemcitabine for phase II evaluation on this schedule was 900 mg/m2. Five patients had objective responses (one complete response and four partial responses; response rate, 19.2%; 95% confidence interval [CI], 6.5 to 39.3), and 10 patients had improvement of disease-related symptoms (45%; 95% CI, 24 to 67). After a median follow-up of 17.7 months (range, 7.8 to 24.8 months), the median progression-free survival and overall survival times were 7.4 months (95% CI, 3.3 to 11.4) and 10.3 months (95% CI, 8.1 to 12.5), respectively. CONCLUSION: The MTD of gemcitabine when combined with 5-FU via PVI on this schedule was 1,000 mg/m2/ wk; however, on the basis of administered dose-intensity, the recommended dose for additional investigation is 900 mg/m2. This combination chemotherapy regimen was well tolerated and showed promising antitumor activity in the treatment of pancreatic cancer. (+info)The effects of vapreotide, a somatostatin analogue, on gastric acidity, gallbladder emptying and hormone release after 1 week of continuous subcutaneous infusion in normal subjects. (4/472)
AIMS: Somatostatin analogues (e.g. vapreotide) are used for treatment of acromegaly, endocrine tumours and variceal bleeding. The pharmacodynamic effects of vapreotide have, however, not been documented in the gastrointestinal tract. The aim of this study was to investigate the effects of continuous vapreotide administration on gastric acidity, gallbladder contraction and hormone release. METHODS: Ten healthy males participated in this randomised, placebo-controlled, double-blind, crossover trial. A constant vapreotide (or placebo) infusion (1.5 mg day(-1) s.c.) was given for 7 days with a portable pump. Intragastric pH was monitored on days 2 and 7. Gallbladder volume was sonographically assessed and the maximal ejection fraction was calculated. In addition basal and postprandial plasma levels of gastrin and cholecystokinin (CCK) were measured. RESULTS: After an initial increase in the median 24 h intragastric pH to a value of 2.6 on day 2, vapreotide's effect on pH decreased: (day 7: median pH=1.9; respective placebo values were 1.7 and 1.5). On the same days with vapreotide treatment, gallbladder contraction and plasma levels of CCK were reduced; maximal ejection fractions after meal stimulation were 18% and 20% (respective placebo values were 57% and 62%). Plasma gastrin levels were not changed with vapreotide treatment. CONCLUSIONS: The short lasting effect of vapreotide on intragastric acidity suggests a down-regulation of somatostatin receptors during treatment. The lack of effect on gastrin indicates that the effects on gastric pH are not mediated by gastrin. Constant vapreotide infusion (but not placebo) reduced gallbladder contraction suggesting a long-lasting effect on biliary function. (+info)Self-intoxication with morphine obtained from an infusion pump. (5/472)
A 36-year-old Caucasian male was found unresponsive by his wife. He had white foam around his mouth and was pronounced dead shortly thereafter. He had a history of back pain and was treated with intrathecal morphine because of his previous addiction to oral opiate medications. Because of crimping of the pump catheter, it was replaced 4 days before his death. Toxicological findings included urine screen positive for amitriptyline, nortriptyline, opiates, hydrocodone metabolites, ibuprofen, acetaminophen, caffeine, nicotine, and metabolite. Drug concentrations were as follows: blood, 0.260 mg/L amitriptyline, 0.160 mg/L nortriptyline, 0.460 mg/L unconjugated morphine, and 0.624 mg/L total morphine; vitreous humor, 0.034 mg/L unconjugated morphine and 0.080 mg/L total morphine; and cerebrospinal fluid, 0.099 mg/L unconjugated morphine and 0.095 mg/L total morphine. Shortly after death, the volume of the residual pump reservoir was only 8 mL instead of the expected 17 mL. Testing by the FDA showed that the pump was functional. The residual content of the pump accounted for only 230 mg instead of the expected 488 mg. The high blood-morphine concentrations did not correlate with the intrathecal infusion dose. The symptoms were consistent with opiate overdose, possibly by injection of morphine withdrawn from the pump reservoir. The cause of death was determined to be fatal morphine self-intoxication, and the manner of death was accidental. This case is intended to alert regulatory agencies, pain management health professionals, pathologists, and toxicologists to the abuse potential of one of the newer analgesic-delivery systems. (+info)Glutamate augments retrovirus-induced immunodeficiency through chronic stimulation of the hypothalamic-pituitary- adrenal axis. (6/472)
The mechanisms for activating the hypothalamic-pituitary-adrenal (HPA) axis and the roles glucocorticoids play in the pathogenesis of chronic infectious disease are largely undefined. Using the LP-BM5 model of retrovirus-induced immunodeficiency, we found alterations in HPA axis function, manifested as an increase in circulating levels of adrenocorticotropic hormone and corticosterone, beginning after only 3 mo of infection. These changes occurred contemporaneously with a shift in the profile of circulating cytokines from a Th1-dominant (IFN-gamma) to Th2-dominant (IL-4, IL-10) phenotype. No significant changes in either circulating IL-1beta, IL-6, or TNF-alpha levels were observed in infected mice. Administering the N-methyl-D-aspartate receptor antagonist MK-801 to infected mice normalized plasma adrenocorticotropic hormone and corticosterone levels, indicating that glutamate was a major activator of the HPA axis. Moreover, MK-801 treatment of late-stage mice also reversed the type 1 to type 2 cytokine shift to a degree comparable or superior to treatment with the glucocorticoid receptor antagonist RU-486. These findings indicate that HPA axis activation during LP-BM5 retrovirus infection is mediated by the chronic hyperactivation of glutamatergic pathways in the hypothalamus. Through this mechanism, the degree of peripheral immunodeficiency observed in the late-stage disease is profoundly augmented. (+info)Enhancement of locomotor activity and conditioned reward to cocaine by brain-derived neurotrophic factor. (7/472)
The mesolimbic dopamine (DA) system has been implicated in drug reward, locomotor sensitization, and responding for reward-related stimuli [termed conditioned reinforcers (CR)]. Here, we investigated the effect of brain-derived neurotrophic factor (BDNF), which enhances the survival and function of dopaminergic neurons, on stimulant-induced locomotor sensitization and responding for CR. In experiment 1, BDNF was infused into the nucleus accumbens (NAc) or ventral tegmental area over 2 weeks via chronically implanted minipumps (1-2.5 microgram/d), and the psychomotor stimulant effects of cocaine (5-15 mg/kg, i.p.) were studied. We found that BDNF enhanced the initial stimulant effects of cocaine and seemed to facilitate the development of sensitization to repeated cocaine doses. In experiment 2, we studied the effects of intra-NAc BDNF infusions on responding for CR. BDNF-treated rats showed twice as many CR responses compared with controls when saline was first administered. BDNF enhanced responding on the CR lever more than four times that seen in control animals after a cocaine injection (10 mg/kg, i.p.). The enhanced response to cocaine in BDNF-treated animals persisted for more than a month after the BDNF infusions had stopped, indicating long-lasting changes in the mesolimbic DA system caused by BDNF administration. In experiment 3, we examined locomotor sensitization to cocaine in heterozygous BDNF knock-out mice and found that the development of sensitization was delayed compared with wild-type littermates. These results demonstrate the profound effects of BDNF on the enhancement of both cocaine-induced locomotion and facilitation of CR and suggest a possible role for BDNF in long-term adaptations of the brain to cocaine. (+info)Comparison of recovery of propofol and methohexital sedation using an infusion pump. (8/472)
Two sedative anesthetic agents administered by an infusion pump were compared during third molar surgery. Forty American Society of Anesthesiologists (ASA) class I or II volunteers were randomly allocated to two groups. All subjects received supplemental oxygen via a nasal hood, fentanyl (0.0007 mg/kg intravenous [i.v.] bolus), and midazolam (1 mg/2 min) titrated to effect. Patients then received either 0.3 mg/kg of methohexital or 0.5 mg/kg of propofol via an infusion pump. Upon completion of the bolus, a continuous infusion of 0.05 mg/kg/min methohexital or 0.066 mg/kg/min propofol was administered throughout the procedure. Hemo-dynamic and respiratory parameters and psychomotor performance were compared for the two groups and no significant differences were found. The continuous infusion method maintained a steady level of sedation. Patients receiving propofol had a smoother sedation as judged by the surgeon and anesthetist. (+info)Postoperative pain is typically managed with pain medication, which may include opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), or other types of medications. The goal of managing postoperative pain is to provide effective pain relief while minimizing the risk of complications such as addiction, constipation, or nausea and vomiting.
In addition to medication, other techniques for managing postoperative pain may include breathing exercises, relaxation techniques, and alternative therapies such as acupuncture or massage. It is important for patients to communicate with their healthcare provider about the severity of their pain and any side effects they experience from medication, in order to provide effective pain management and minimize complications.
Postoperative pain can be categorized into several different types, including:
* Acute pain: This type of pain is intense but short-lived, typically lasting for a few days or weeks after surgery.
* Chronic pain: This type of pain persists for longer than 3 months after surgery and can be more challenging to manage.
* Neuropathic pain: This type of pain is caused by damage to nerves and can be characterized by burning, shooting, or stabbing sensations.
* Visceral pain: This type of pain originates in the internal organs and can be referred to other areas of the body, such as the back or abdomen.
Infusion pump
Total intravenous anaesthesia
Steven Shafer
Paragon Innovations
Johnson Matthey Battery Systems
Phulchand Prithvi Raj
Baxter International
Intrathecal pump
Structural engineering
Medical device
Static program analysis
Insulin (medication)
Glossary of diabetes
Power supply
Vasoactivity
Cardinal Health
Omeprazole
Elastomeric pump
Insulin pump
Ghulam Muhammad Mahar Medical College
Hyperinsulinemic hypoglycemia
Katherine Crothall
CareFlight
Infusion therapy
Auditory brainstem response
Minimed Paradigm
Intensive insulin therapy
Anesthesia
Infusion set
Davide Sorrenti
Milk-alkali syndrome
Henry Buchwald
Kobe Bryant
Glucommander
Index of biomedical engineering articles
Ken Strauss
Benzodiazepine overdose
Behavioral neuroscience
Cholestasis
Convection enhanced delivery
Tricuspid atresia
List of International Organization for Standardization standards, 1-1999
Hospira
Biomedical equipment technician
Apheresis
Gonadorelin
Air India
CXL 1020
Treprostinil
Teva Pharmaceuticals
GameStop short squeeze
Heptavalent botulism antitoxin
Medical equipment management
Dean Kamen
Aortic valve replacement
Stress ulcer
Infusion Pump | Renesas
Class 2 Device Recall Plum A Infusion Pump, Single Channel
Epidemiologic Notes and Reports Deaths among Patients Using
Continuous Subcutaneous Insulin Infusion Pumps -- United States
Ambulatory Pump Safety: Managing Home Infusion Patients Admitted to the ED And Hospital | Institute For Safe Medication...
Toxicities and complications of implanted pump hepatic arterial and intravenous floxuridine infusion - PubMed
US Patent for Ambulatory infusion pump Patent (Patent # 5,100,389 issued March 31, 1992) - Justia Patents Search
Infusion Pumps
low price infusion pump suppliers
Usability of volumetric infusion pumps in pediatric intensive care. | Rev Esc Enferm USP;55: e03712, 2021. | MEDLINE
Zerone Volumetric Infusion Pump | HALOMEDICALS SYSTEMS LIMITED
Post-pandemic Era) - Global Medical Intravenous Infusion Pump Market Segment Research Report 2022 - RnR Market Research
Insights on the Infusion Therapy Global Market to 2026
Infusion Pump Market Size To Worth $24.6 Billion By 2030
Micro Syringe Pump Latest Price, Micro Infusion Pump Exporter from China
DailyMed - TREPROSTINIL injection, solution
FDA: Do Your Part. #BeCyberSmart | 24x7
Epidural Nerve Block: Overview, Indications, Contraindications
Documentation | Santé Montérégie Portal
Insulin pumps: MedlinePlus Medical Encyclopedia
HBM - Medical Device Network
Synchromed Pump Archives - AboutLawsuits.com
Levemir FlexTouch U-100 Insulin Subcutaneous: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD
caseyjohnellis - Press and Speaking History - Google Sheets
NIH Clinical Center Search the Studies: Study Number, Study Title
Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital...
Intravenous6
- Toxicities and complications were prospectively analyzed in patients with liver metastases receiving hepatic intra-arterial (IA) and systemic intravenous (IV) floxuridine (FUDR) with the Infusaid (Intermedics-Infusaid Corp., Norwood, MA) implantable pump. (nih.gov)
- Who are the Major Players in Medical Intravenous Infusion Pump Market? (rnrmarketresearch.com)
- Use intravenous (IV) infusion if subcutaneous infusion is not tolerated. (nih.gov)
- Chronic intravenous infusions delivered using an external infusion pump with an indwelling central venous catheter are associated with the risk of blood stream infections (BSIs) and sepsis, which may be fatal. (nih.gov)
- Infusion pumps are used for the intravenous administration of infusions. (medicaldevice-network.com)
- used routinely in hospitals to maintain a patent intravenous line, to administer antineoplastic agents and other drugs in thromboembolism, heart disease, diabetes mellitus ( INSULIN INFUSION SYSTEMS is also available), and other disorders. (nih.gov)
Volumetric infusion pumps1
- Usability of volumetric infusion pumps in pediatric intensive care. (bvsalud.org)
Unresectable colorectal liver metastases1
- 10. Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. (nih.gov)
Syringe4
- Promising Quality In Our LINSZ-10 Series AIO Pump, LINZ-9 Series Micro Syringe Pump, LINZ-8 Series Micro Syringe Pump, etc. (leienmedical.com)
- Shanghai Leien Medical Equipment Co., Ltd. is a hi-tech company in Shanghai, China, indulged in manufacturing LINZ-8B Double Channel Micro Syringe Pump, Triple Channel LINZ-9C Micro Syringe Pump, LINSZ-10C AIO Pump (I Infusion And II Syringe), etc. (leienmedical.com)
- Our unit of manufacturing Triple Channel LINZ-9C Micro Syringe Pump, LINZ-8B Double Channel Micro Syringe Pump, LINSZ-10C AIO Pump (I Infusion And II Syringe), etc., spreads across 1500 square meters of land. (leienmedical.com)
- For example, delivery of isocyanates was accomplished by interfacing a KD Scientific 200 Two-Syringe Infusion Pump with an EZSTARTER airbrush with an atomizing nozzle from PAASCHE. (cdc.gov)
Implantable1
- 9. [Long-term regional chemotherapy for colorectal liver metastasis: significance of hepatic arterial anatomy in the surgical placement of the implantable infusion device]. (nih.gov)
Floxuridine infusion1
- 7. Multidetector CT arteriography with volumetric three-dimensional rendering to evaluate patients with metastatic colorectal disease for placement of a floxuridine infusion pump. (nih.gov)
Ambulatory13
- Since then, the availability of lightweight ambulatory pumps has made infusion therapy possible in alternative settings outside the hospital, including in the home. (ismp.org)
- A new market research study suggests that the use of ambulatory pumps is commonplace and will continue to grow at an annual rate of about 9% over the next 5 years. (ismp.org)
- Ongoing technology developments and newer applications of ambulatory pumps in the home are further driving an increase in their use. (ismp.org)
- Today, ambulatory pumps are being used to deliver various medications ( Table 1 ) to treat a wide array of diseases and conditions, from diabetes to chronic pain. (ismp.org)
- Examples of medications/medication classes and solutions commonly administered at home via ambulatory pumps. (ismp.org)
- The ambulatory pump marketplace is diverse, so the devices rarely have standard components. (ismp.org)
- Often, healthcare providers are not familiar with all the ambulatory pumps in use, and most patients who use these devices are ill informed, leading to serious errors-the most dangerous of which is overinfusion. (ismp.org)
- For example, just recently in our June 18, 2015 newsletter, we described numerous overinfusions of fluorouracil caused by misprogramming a CADD ambulatory infusion pump and misusing a rate-specific elastomeric EASYPUMP . (ismp.org)
- So, what happens in your hospital when a patient using an ambulatory pump to deliver a medication or solution is admitted to the ED or hospital? (ismp.org)
- Turning off the ambulatory pump without understanding its purpose and contents could lead to serious, even fatal, events. (ismp.org)
- The ambulatory infusion pump is provided with a preloaded spring having a fixed spring constant. (justia.com)
- This invention relates to an ambulatory infusion pump. (justia.com)
- More particularly, this invention relates to an ambulatory infusion pump for dispensing fluids such as medications. (justia.com)
Hepatic7
- 1. Saphenous vein graft conduits for insertion of hepatic arterial infusion pumps in patients with abnormal hepatic arterial anatomy. (nih.gov)
- 4. Laparoscopic placement of hepatic artery infusion pumps: technical considerations and early results. (nih.gov)
- 8. Hepatic artery infusion of chemotherapy as a treatment for hepatic metastases from colorectal cancer. (nih.gov)
- 11. Extrahepatic biliary stenoses after hepatic arterial infusion (HAI) of floxuridine (FUdR) for liver metastases from colorectal cancer. (nih.gov)
- 13. Adjuvant hepatic arterial infusion after curative resection of colorectal liver metastases using removable intra-arterial catheters with shape-memory alloy. (nih.gov)
- 14. Laparoscopic radiofrequency ablation and hepatic artery infusion pump placement in the evolving treatment of colorectal hepatic metastases. (nih.gov)
- 16. Hepatic arterial infusion chemotherapy through a port-catheter system as preoperative initial therapy in patients with advanced liver dysfunction due to synchronous and unresectable liver metastases from colorectal cancer. (nih.gov)
20223
- The global infusion pump market size is expected to reach USD 24.6 Billion by 2030, with a CAGR of 8.3% from 2022 to 2030. (marketstatsnews.com)
- 150+ Pages Report] As per the latest Research and survey report issued by Precedence Research, the global infusion pump market was valued at around USD 12 billion in 2021 and is expected to register revenues worth USD 24.6 billion by the end of 2030 , growing at an exceptional CAGR of approximately 8.3% between 2022 and 2030. (marketstatsnews.com)
- A recent study by Precedence Research on the infusion pump market offers a forecast for 2022 and 2030. (marketstatsnews.com)
Chemotherapy2
- In our November 20, 2014 newsletter, we published an event in which both a patient and clinicians in the ED mistakenly believed an elastomeric DOSI-FUSER pump had malfunctioned and delivered an overinfusion of fluorouracil when it had not, leading to the omission of a large portion of the prescribed chemotherapy after the infusion was disconnected prematurely. (ismp.org)
- 6. [Complication due to arterial infusion chemotherapy for liver metastasis from colorectal cancer]. (nih.gov)
Patient's2
- An infusion pump is an instrument that can accurately control the number of infusion drops or infusion flow rate to ensure that a drug can be evenly distributed, and the amount of the drug can accurately and safely enter a patient's body. (renesas.com)
- 5 For example, in a 2014 consensus statement, the American Association of Clinical Endocrinologists and the American College of Endocrinology encourage hospitalized patients and their admitting physicians to not discontinue an insulin pump, but rather to consult the specialist responsible for the patient's insulin pump management if the patient cannot manage his or her own pump. (ismp.org)
Bolus2
- Most pumps have a 'bolus wizard' to help calculate the bolus dose based on your blood glucose level and the meal (grams of carbohydrate) you are eating. (medlineplus.gov)
- You can program the pump to deliver the bolus doses in different patterns. (medlineplus.gov)
Analyze2
- To analyze the usability of two infusion pump models in a Pediatric Intensive Care Unit . (bvsalud.org)
- 2. Complete coverage of all the segments in the infusion therapy market to analyze the trends, developments in the global market and forecast of market size up to 2026. (globenewswire.com)
Ventilators1
- Taking care of ICU patients requires a lot of special skills on top of dedication and meticulous attention to detail," she said, mentioning among them central line insertion, intubation, and operating machines like infusion pumps and ventilators. (who.int)
Subcutaneous2
- Continuous subcutaneous infusion is the preferred mode. (nih.gov)
- Children and young adults aged 7-20 years with congenital hypoparathyroidism (N = 12) were randomized to receive PTH 1-34, delivered either by twice-daily subcutaneous injection or insulin pump for 13 weeks, followed by crossover to the opposite delivery method. (nih.gov)
Types of insulin1
- There are different types of insulin pumps. (nih.gov)
Medication2
- As with any medication delivery system, patient safety can be jeopardized if the devices are mishandled when filling, programming, attaching, and monitoring the pumps. (ismp.org)
- Data analyzed from the Armis Asset Intelligence and Security Platform , which tracks over three billion assets, found nurse call systems to be the riskiest* IoMT device, followed by infusion pumps and medication dispensing systems. (businesswire.com)
Injection2
- To compare the response with synthetic human parathyroid hormone (PTH) 1-34 delivered by twice-daily injection vs insulin pump in children with severe congenital hypoparathyroidism due to calcium receptor mutation or autoimmune polyglandular syndrome type 1. (nih.gov)
- People with type 1 diabetes control their blood glucose level by checking it and taking insulin, either by injection or through an insulin infusion pump , several times a day. (nih.gov)
20201
- The report predicts the global infusion therapy market to grow with a CAGR of 4.1% over the forecast period from 2020-2026. (globenewswire.com)
Medtronic7
- A Medtronic SynchroMed II lawsuit claims the drug infusion pump repeatedly overdosed a woman when she had the drug reservoir refilled. (aboutlawsuits.com)
- Thousands of Medtronic SynchroMed II infusion pumps are being recalled due to the risk of the motor stalling. (aboutlawsuits.com)
- Medtronic says a new system to be used with its SynchroMed infusion pump will help wean patients off of addictive opoid pain killers. (aboutlawsuits.com)
- Some older Medtronic SynchroMed II infusion pumps may have a more than 3% chance of battery failure, which could necessitate revision surgery, the company warns. (aboutlawsuits.com)
- Medtronic has issued a warning letter indicating that its SynchroMed II infusion pump has been linked to drug overdoses that have left at least two dead. (aboutlawsuits.com)
- Problems with Medtronic Synchromed II Infusion Pump cause a Pennsylvania man to receive an over delivery of pain medications, resulting in hospitalization and permanent injuries. (aboutlawsuits.com)
- Medtronic and the FDA have entered into a consent decree over manufacturing violations involving the Synchromed II Infusion Pump. (aboutlawsuits.com)
Insights2
- The report has engulfed a chapter on the global infusion pump market's competitive landscape, which provides detailed analysis and insights on companies offering infusion pump. (marketstatsnews.com)
- Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global infusion therapy market over the period of 2018 to 2026. (globenewswire.com)
Complication1
- Hypoglycemia is a well-recognized complication of intensive control of diabetes (3), but further information is necessary before conclusions can be drawn as to whether hypoglycemia was the cause of death in a greater-than-expected number of patients using insulin infusion devices. (cdc.gov)
Insulin delivery3
- When patients with insulin pumps are evaluated in the ED or admitted to the hospital, they typically have more knowledge and expertise with using the pump for insulin delivery than the medical professionals who are handling their care. (ismp.org)
- A separate wireless device programs insulin delivery from the pump. (medlineplus.gov)
- This allows you (or in some cases the pump) to stop insulin delivery if blood glucose is becoming too low. (medlineplus.gov)
Patients7
- patients used pumps from more than 1 manufacturer. (cdc.gov)
- Further investigation of the cases reported here is warranted, and surveillance of deaths among patients using insulin infusion pumps should be established. (cdc.gov)
- Editorial Note: No data on morbidity or mortality are currently available from a group of diabetics under intensive control and not using infusion pumps, i.e., comparable to patients using infusion pumps. (cdc.gov)
- Before the 1980s, patients had to be hospitalized to receive various types of infusion therapies to treat diseases unresponsive to oral medications. (ismp.org)
- Insulin pumps provide another example of a unique challenge to clinicians when patients with these devices present for treatment. (ismp.org)
- In 2007, about 374,000 patients with type 1 diabetes were using insulin pumps. (ismp.org)
- 2 Today, more than half a million patients with type 1 and type 2 diabetes are using insulin pumps. (ismp.org)
Doses1
- The insulin infusion pump will deliver small doses of insulin throughout the day when blood glucose levels are not in your target range. (nih.gov)
20161
- In the year 2016, we launched AIO Pump, which is one of the milestones in the history of Infusion Pumps. (leienmedical.com)
Forecast period1
- The study also provides the dynamics that are responsible for influencing the future status of the infusion pump market over the forecast period. (marketstatsnews.com)
Reservoir3
- Traditional pumps include an insulin reservoir (cartridge) and a catheter. (medlineplus.gov)
- Patch pumps are worn directly on the body with the reservoir and tubes inside a small case. (medlineplus.gov)
- Pumps come with features such as waterproofing, touchscreen, and alerts for dosage time and insulin reservoir capacity. (medlineplus.gov)
Medications1
- Alarm problems and infusion pump medications errors are on the top of the list of hospital problems that need to be addressed. (klinespecter.com)
Devices4
- The Plum A+ Infusion Systems are a multi-purpose family of devices that provides precise delivery of multiple therapies across the general spectrum of clinical care. (fda.gov)
- The Plum A+ family infusion pumps are self-contained, microprocessor based infusion devices. (fda.gov)
- Insulin infusion pumps are open loop devices that administer insulin subcutaneously at a constant low level and deliver added amounts before meals. (cdc.gov)
- Infusion devices have also been known, such as described in U.S. Pat. (justia.com)
Catheter4
- An insulin pump is a small device that delivers insulin through a small plastic tube (catheter). (medlineplus.gov)
- Tubing connects the catheter to a pump that has a digital display. (medlineplus.gov)
- Insulin flows from the pump through a plastic tube that connects to a smaller tube, called a catheter , which has a needle that is inserted under the skin and stays in place for several days. (nih.gov)
- Another type of pump attaches directly to the skin with an adhesive pad and gives insulin through a catheter inserted under the skin. (nih.gov)
Intensive1
- While none of the deaths could be attributed to the infusion pumps, some deaths may have been due to the intensive glycemia control used as a therapeutic goal. (cdc.gov)
Continuous glucose3
- Some pumps can connect or communicate with a glucose sensor to monitor blood glucose levels (continuous glucose monitor or CGM). (medlineplus.gov)
- Many pumps now communicate wirelessly with continuous glucose monitors (CGMs). (medlineplus.gov)
- An artificial pancreas system uses a continuous glucose monitor, an insulin pump, and a program stored on the pump or a smartphone (top). (nih.gov)
Qualitative1
- The report on the global infusion therapy market provides qualitative and quantitative analysis for the period from 2018 to 2026. (globenewswire.com)
Device2
- This solution is an intelligent infusion device. (renesas.com)
- The device pumps insulin continuously day and night. (medlineplus.gov)
Diabetes2
- Insulin pumps can help some people with diabetes have more control in managing blood glucose. (medlineplus.gov)
- Your diabetes team (and the pump manufacturer) will help you learn everything you need to know to use the pump successfully. (medlineplus.gov)
Therapy5
- The study on infusion therapy market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2018 to 2026. (globenewswire.com)
- The report on infusion therapy market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global infusion therapy market over the period of 2018 to 2026. (globenewswire.com)
- The global infusion therapy market is segmented on the basis of product type, application, and end user. (globenewswire.com)
- 1. Comprehensive analysis of the global as well as regional markets of the infusion therapy market. (globenewswire.com)
- 3. Comprehensive analysis of the companies operating in the global infusion therapy market. (globenewswire.com)
Alarm1
- This Volumetric Infusion Pump has visual and audio alarm function and safety function. (halomedicals.com)
Type2
Flow rate1
- It is another object of the invention to be able to change the flow rate of an infusion pump. (justia.com)
Dynamics1
- This report explicates on vital dynamics such as the drivers, restraints, and opportunities for key market players, along with key stakeholders as well as emerging players associated with the manufacturing of infusion pump. (marketstatsnews.com)
Patient2
- Thus, although 4,000 pumps are currently estimated to be in use in the United States, the number of patient years of insulin pump use may be substantially less than the number of pumps might indicate. (cdc.gov)
- It is another object of the invention to provide an infusion pump which can be worn by a patient and used in a reliable manner. (justia.com)
Market3
- The study analyzes crucial trends that are currently determining the growth of the infusion pump market. (marketstatsnews.com)
- A detailed assessment of the infusion pump market value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. (marketstatsnews.com)
- A list of prominent companies operating in the infusion pump market along with their product portfolio enhances the reliability of this comprehensive research study. (marketstatsnews.com)
Substantially1
- It is another object of the invention to provide an infusion pump which is able to maintain a substantially uniform rate of discharge of fluid over time. (justia.com)
Sets1
- Dedicated Mindray infusion sets be used delivering high ac. (acailangola.com)
Size1
- Most insulin pumps are about the size of a small mobile phone, but models keep getting smaller. (medlineplus.gov)
Worn1
- The insulin pump can be worn on a belt, stored in a pocket, or attached directly to the skin (bottom). (nih.gov)
Fluid4
- The biasing force of the spring and the stroke of the piston are coordinated so as to maintain a pressure on the fluid being dispensed from the pump housing which decreases at a slow rate and within a range of about 15% of the referenced pressure. (justia.com)
- Further, infusion pumps have been known which employ constant force springs to impose a driving force on a piston in order to expel fluid from a housing. (justia.com)
- Briefly, the invention provides an infusion pump which is able to deliver fluid over a prolonged period of time at a pressure which changes by less than about plus or minus 15% of the referenced pressure over the total time period. (justia.com)
- To this end, the infusion pump is comprised of a tubular housing for a fluid, a piston slidably mounted in the housing and a spring within the housing for imposing a biasing force on the piston which decreases during movement of the piston from a filled position to an empty position. (justia.com)
Rate1
- Maximum infusion rate: 150. (acailangola.com)
Health1
- Talk to your health care provider about which pump is right for you. (medlineplus.gov)
User1
- This One-channel Volumetric Infusion Pump is design ergonomically and user friendly. (halomedicals.com)